Platelet reactivity characterized prospectively: a determinant of outcome 90 days after percutaneous coronary intervention
Summary
This summary is machine-generated.Assessing platelet glycoprotein IIb/IIIa activation can identify patients at high risk for adverse events after percutaneous coronary interventions (PCI). This helps stratify patients for better risk management post-PCI.
Area Of Science
- Cardiovascular Medicine
- Hematology
- Interventional Cardiology
Background
- Platelet activation is crucial in percutaneous coronary interventions (PCI) complications.
- Interindividual variability in glycoprotein (GP) IIb/IIIa activation exists.
- Assessing GP IIb/IIIa activation may differentiate risks after PCI.
Purpose Of The Study
- To prospectively evaluate if GP IIb/IIIa activation levels can stratify patients into low- and high-risk groups for adverse events post-PCI.
- To determine the predictive value of platelet reactivity for early and late complications after PCI.
Main Methods
- 112 patients undergoing PCI were studied.
- Platelet reactivity was measured using flow cytometry, assessing GP IIb/IIIa activation in response to ADP.
- Patients were categorized into high and low platelet reactivity groups based on median GP IIb/IIIa activation.
Main Results
- The high platelet reactivity group had a significantly higher incidence of a composite endpoint (myocardial infarction, urgent/repeat revascularization) at 90 days (26.8% vs. 7.1%, P=0.01).
- This difference was most pronounced between 30-90 days post-PCI (16.7% vs. 1.9%, P=0.02).
- Repeat revascularization was more frequent in the high reactivity group (17.9% vs. 3.6%, P=0.029).
Conclusions
- Prospective assessment of platelet GP IIb/IIIa activation effectively stratifies patients.
- This stratification identifies individuals at higher risk for adverse cardiovascular events following PCI.
- Platelet function testing can guide risk assessment and management strategies in PCI patients.
View abstract on PubMed